Therapeutic use of a thienylcyclohexylamine derivative
AssigneeSociete de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)
InventorsGuy Lallement, Pierre D'Arbigny, Jean-Marc Kamenka
Life of this patent
Estimating the term…
Abstract
A method of inhibiting effects of exogenous neurotoxic or neurotoxinic products in warm-blooded animals comprising administering to warm-blooded animals before exposure to said products an inhibitorily effective amount of reversible cholinesterase inhibitor selected from the group consisting of pyridostigmine and physostigmine followed by administration of an inhibitorily effective amount of 2-methyl-1-(1-piperidinyl)-1-(2-thienyl)-cyclohexane in substantially pure racemic, diastereoisomeric or enantiomeric form.
Claims27
Use of thienylcyclohexylamine corresponding to the formula 2-methyl-1-(1-piperidinyl)-1-(2-thienyl) cyclohexane, in substantially pure racemic, diastereoisomeric or enantiomeric form, by itself or in combination with other pharmaceutically active substances, for the preparation of a medicament intended to limit or inhibit the effects due to neurotoxic products or those containing neurotoxin.
As a medicament, a product containing thienylcyclohexylamine corresponding to the formula 2-methyl-1-(1-piperidinyl)-1-(2-thienyl) cyclohexane, in substantially pure racemic, diastereoisomeric or enantiomeric form, combined with at least one pharmaceutically active substance capable of limiting or inhibiting the effects due to neurotoxic products or those containing neurotoxin.
Product containing thienylcyclohexylamine and at least one substance chosen from anticholinergic, anticonvulsive substances and substances which reactivate cholinesterases as a combination product for simultaneous or separate use, or use spread out over time to limit or inhibit the effects due to neurotoxic products or those containing neurotoxin.
Dependencies are inferred from the claim text.